Carmot, Amgen in discovery deal

Carmot Therapeutics Inc. (San Francisco, Calif.) and Amgen Inc. (NASDAQ:AMGN) partnered to use Carmot's Chemotype Evolution fragment-based lead discovery technology to discover novel drug leads for two undisclosed targets selected by Amgen. Carmot and Amgen will collaborate to identify and optimize drug candidates. Amgen will be responsible for clinical development. Carmot will receive an undisclosed upfront payment and research funding. The company is also eligible for undisclosed milestones, plus royalties. ...